{"schema_version":"1","generated_at":"2026-10-29T18:49:01.495Z","data_as_of":"2026-10-27","url":"https://www.findmykol.com/kol/kieuhoa-vo","json_url":"https://www.findmykol.com/kol/kieuhoa-vo/profile.json","record_kind":"full","profile_kind":"clinical","person":{"slug":"kieuhoa-vo","name":"Kieuhoa Vo","credential":"MD","title":"Associate Professor, Pediatrics","specialty":"Hematology / Oncology","specialty_raw":"Pediatric Hematology-Oncology","therapeutic_area":"Sarcoma","therapeutic_areas":["Sarcoma","Pediatric","Neuro-Oncology","Leukemia"],"institution":"University of California, San Francisco","institution_url":"https://www.findmykol.com/institution/university-of-california-san-francisco","city":"San Francisco","state":"CA","region":{"label":"West","url":"https://www.findmykol.com/region/west"},"country":{"name":"United States","code":"US","status":"verified"}},"identifiers":{"npi":"1346403409","orcid":"0000-0002-9281-7485","openalex":"A5069053611"},"summary":"Kieuhoa Vo is Associate Professor, Pediatrics at University of California, San Francisco. OpenAlex indexes 57 publications with 1,355 citations (h-index 18); ClinicalTrials.gov lists 12 registered studies with this person as an investigator.","overview":{"text":"Kieuhoa Vo, MD, is Associate Professor, Pediatrics at University of California, San Francisco. The public record shows 57 publications with 1,355 citations (h-index 18), centered on Sarcoma Diagnosis and Treatment, Neuroblastoma Research and Treatments, Glioma Diagnosis and Treatment. It also documents an investigator role on 12 registered clinical trials, 1 NIH-funded awards (2024–2026).","bullets":["Most recent indexed publication: 2026 · Clinical cancer research","Top research focus: Sarcoma Diagnosis and Treatment","12 registered trials on ClinicalTrials.gov"],"generated_at":"2026-10-28"},"focus":{"indications":[{"label":"Neuroblastoma","therapeutic_area":"Oncology","trials":8,"topics":0,"strength":24},{"label":"Sarcoma","therapeutic_area":"Oncology","trials":4,"topics":1,"strength":13},{"label":"Coma","therapeutic_area":"Neurology","trials":4,"topics":0,"strength":12},{"label":"Lymphoma","therapeutic_area":"Oncology","trials":3,"topics":0,"strength":9},{"label":"Sarcoma, Ewing","therapeutic_area":"Oncology","trials":3,"topics":0,"strength":9},{"label":"Hepatoblastoma","therapeutic_area":"Oncology","trials":3,"topics":0,"strength":9},{"label":"Neuro-Oncology / Glioma","therapeutic_area":"Oncology","trials":2,"topics":1,"strength":7},{"label":"Lymphoma, Non-Hodgkin","therapeutic_area":"Oncology","trials":2,"topics":0,"strength":6},{"label":"Glioma","therapeutic_area":"Oncology","trials":2,"topics":0,"strength":6},{"label":"Hodgkin Disease","therapeutic_area":"Oncology","trials":2,"topics":0,"strength":6},{"label":"Central Nervous System Neoplasms","therapeutic_area":"Oncology","trials":2,"topics":0,"strength":6},{"label":"Medulloblastoma","therapeutic_area":"Oncology","trials":2,"topics":0,"strength":6},{"label":"Rhabdomyosarcoma","therapeutic_area":"Oncology","trials":2,"topics":0,"strength":6},{"label":"Wilms Tumor","therapeutic_area":"Oncology","trials":2,"topics":0,"strength":6},{"label":"Myosarcoma","therapeutic_area":"Oncology","trials":2,"topics":0,"strength":6},{"label":"Ganglioneuroblastoma","therapeutic_area":"Oncology","trials":2,"topics":0,"strength":6},{"label":"Leukemia (AML/ALL/CML/CLL)","therapeutic_area":"Oncology","trials":1,"topics":1,"strength":4},{"label":"Ependymoma","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Neuroectodermal Tumors, Primitive, Peripheral","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Rhabdoid Tumor","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Histiocytosis","therapeutic_area":"Hematology","trials":1,"topics":0,"strength":3},{"label":"Neoplasms, Germ Cell and Embryonal","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Colorectal Cancer","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Hepatobiliary Cancer","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Melanoma","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Endometrial Neoplasms","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Desmoid Tumors","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Fibroma","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Diffuse Intrinsic Pontine Glioma","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"MDS / MPN","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Leukemia, Myeloid, Acute","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Leukemia, Myelomonocytic, Juvenile","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Neuroectodermal Tumors","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3}],"research_topics":["Sarcoma Diagnosis and Treatment","Neuroblastoma Research and Treatments","Glioma Diagnosis and Treatment","Acute Lymphoblastic Leukemia research","Neurofibromatosis and Schwannoma Cases"],"works_with":{"total":7,"shown":3,"withheld":4,"rows":[{"name":"Children's Oncology Group","trials":5,"payments":0,"mentions":5},{"name":"National Cancer Institute (NCI)","trials":2,"payments":0,"mentions":2},{"name":"Jubilant DraxImage Inc.","trials":1,"payments":0,"mentions":1}]}},"scholarship":{"works_count":57,"cited_by_count":1355,"h_index":18,"i10_index":26,"pubmed_count":8,"latest_activity_year":2026,"source":"works"},"trials":{"count":12,"shown":3,"withheld":9,"matched_by":"identity-adjudicated record","rows":[{"nct":"NCT07437963","title":"Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse","phase":"PHASE1/PHASE2","status":"NOT_YET_RECRUITING","role":"Investigator","sponsor":"National Cancer Institute (NCI)","source_url":"https://clinicaltrials.gov/study/NCT07437963","trial_url":"https://www.findmykol.com/trial/NCT07437963"},{"nct":"NCT07085338","title":"A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma","phase":"PHASE2","status":"RECRUITING","role":"Investigator","sponsor":"St. Jude Children's Research Hospital","source_url":"https://clinicaltrials.gov/study/NCT07085338","trial_url":"https://www.findmykol.com/trial/NCT07085338"},{"nct":"NCT06620302","title":"Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma","phase":"PHASE1/PHASE2","status":"RECRUITING","role":"Investigator","sponsor":"Children's Oncology Group","source_url":"https://clinicaltrials.gov/study/NCT06620302","trial_url":"https://www.findmykol.com/trial/NCT06620302"}],"source":"trials"},"payments":{"company_count":0,"program_years":{"first":2021,"last":null},"rows_total":0,"shown":0,"withheld":0,"rows":[],"record_url":"https://openpaymentsdata.cms.gov/search?query=1346403409","source":"payments"},"funding":{"award_count":1,"fiscal_years":{"first":2024,"last":2026},"rows_total":3,"shown":3,"withheld":0,"rows":[{"project":"R01CA285681","title":"Circulating biomarkers of clinical response to combination targeted therapies in neuroblastoma","fiscal_year":2026,"amount_usd":535047,"organization":"UNIVERSITY OF CALIFORNIA, SAN FRANCISCO","source_url":"https://reporter.nih.gov/quickSearch/R01CA285681"},{"project":"R01CA285681","title":"Circulating biomarkers of clinical response to combination targeted therapies in neuroblastoma","fiscal_year":2025,"amount_usd":540607,"organization":"UNIVERSITY OF CALIFORNIA, SAN FRANCISCO","source_url":"https://reporter.nih.gov/quickSearch/R01CA285681"},{"project":"R01CA285681","title":"Circulating biomarkers of clinical response to combination targeted therapies in neuroblastoma","fiscal_year":2024,"amount_usd":573379,"organization":"UNIVERSITY OF CALIFORNIA, SAN FRANCISCO","source_url":"https://reporter.nih.gov/quickSearch/R01CA285681"}],"source":"grants"},"congress":{"count":13,"years":{"first":2017,"last":2026},"societies":["AACR","ASCO"],"shown":3,"withheld":10,"rows":[{"title":"Feasibility study of prolonged administration of naxitamab, irinotecan, and temozolomide for patients with relapsed or refractory neuroblastoma.","society":"ASCO","meeting":"ASCO Annual Meeting","year":2026,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps10058","source_url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps10058","status":"verified"},{"title":"Phase II trial of olaparib and ceralasertib in patients with recurrent osteosarcoma: Lung-only resectable cohort efficacy and correlative biomarker results.","society":"ASCO","meeting":"ASCO Annual Meeting","year":2026,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1200/jco.2026.44.16_suppl.10015","source_url":"https://doi.org/10.1200/jco.2026.44.16_suppl.10015","status":"verified"},{"title":"Results of a phase II trial of olaparib in combination with ceralasertib in patients with recurrent and unresectable osteosarcoma.","society":"ASCO","meeting":"ASCO Annual Meeting","year":2025,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1200/jco.2025.43.16_suppl.10005","source_url":"https://doi.org/10.1200/jco.2025.43.16_suppl.10005","status":"verified"}],"source":"congress"},"publications":{"total":8,"shown":5,"withheld":3,"matched_by":"ORCID record, linked to PubMed","recent":[{"title":"A First-in-Pediatric Study of ALRN-6924, a Novel Stapled-Peptide Dual MDM2/MDMX Inhibitor, for Children with Advanced Hematologic and Solid Malignancies.","year":2026,"journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","types":["Clinical Trial, Phase I","Journal Article","Multicenter Study"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/42189874/","status":"verified"},{"title":"Phase I Study of (131)I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial.","year":2025,"journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","types":["Journal Article","Clinical Trial, Phase I","Research Support, N.I.H., Extramural"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/40549985/","status":"verified"},{"title":"A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors.","year":2025,"journal":"Pediatric blood & cancer","types":["Journal Article","Clinical Trial, Phase I","Clinical Trial, Phase II","Multicenter Study","Research Support, N.I.H., Extramural","Research Support, Non-U.S. Gov't"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/40313040/","status":"verified"},{"title":"Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial.","year":2024,"journal":"JCO precision oncology","types":["Journal Article","Clinical Trial, Phase II","Research Support, Non-U.S. Gov't","Research Support, N.I.H., Extramural"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/38935895/","status":"verified"},{"title":"Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to (131) I-MIBG in patients with relapsed/refractory neuroblastoma.","year":2024,"journal":"Pediatric blood & cancer","types":["Journal Article","Research Support, N.I.H., Extramural"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/37885116/","status":"verified"}],"most_cited":{"total":57,"shown":5,"withheld":52,"rows":[{"title":"Clinical, Biologic, and Prognostic Differences on the Basis of Primary Tumor Site in Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project","year":2014,"cited_by_count":217,"type":"article","source_url":"https://doi.org/10.1200/jco.2014.56.1621"},{"title":"Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children’s Oncology Group","year":2018,"cited_by_count":149,"type":"article","source_url":"https://doi.org/10.1038/s41416-018-0212-9"},{"title":"Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results","year":2023,"cited_by_count":144,"type":"article","source_url":"https://doi.org/10.1038/s41591-023-02297-5"},{"title":"Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium","year":2021,"cited_by_count":88,"type":"article","source_url":"https://doi.org/10.1200/jco.21.00703"},{"title":"Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project","year":2015,"cited_by_count":78,"type":"article","source_url":"https://doi.org/10.1002/cncr.29848"}]},"source":"publications"},"network":{"coauthors_total":40,"shown":3,"withheld":37,"coauthors":[{"name":"Steven G. DuBois","coauthored_works":35},{"name":"Katherine K. Matthay","coauthored_works":26},{"name":"Wendy B. London","coauthored_works":15}],"source":"works"},"recognition":{"education":{"total":4,"shown":4,"rows":[{"value":"M.A.S., Clinical Research, University of California, San Francisco, 2015","source_url":"https://profiles.ucsf.edu/kieuhoa.vo","status":"verified","collected_at":"2026-10-28"},{"value":"Pediatric Oncology/Hematology Fellowship, UCSF, 2015","source_url":"https://profiles.ucsf.edu/kieuhoa.vo","status":"verified","collected_at":"2026-10-28"},{"value":"MD, Indiana University School of Medicine, 2008","source_url":"https://profiles.ucsf.edu/kieuhoa.vo","status":"verified","collected_at":"2026-10-28"},{"value":"Board certified: American Board of Pediatrics, Pediatric Hematology-Oncology","source_url":"https://www.ucsfbenioffchildrens.org/providers/dr-kieuhoa-vo","status":"verified","collected_at":"2026-10-28"}]},"roles":{"total":3,"shown":3,"rows":[{"value":"Director, Early Phase Clinical Trials Program (Pediatric Oncology), UCSF","source_url":"https://braintumorcenter.ucsf.edu/people/kieuhoa-t-vo","status":"verified","collected_at":"2026-10-28"},{"value":"Director, MIBG Therapy Program, UCSF","source_url":"https://www.ucsfbenioffchildrens.org/providers/dr-kieuhoa-vo","status":"verified","collected_at":"2026-10-28"},{"value":"Site Principal Investigator, Children's Oncology Group Pediatric Early Phase Clinical Trials Network (PEP-CTN) and New Approaches to Neuroblastoma Therapy (NANT) consortium","source_url":"https://braintumorcenter.ucsf.edu/people/kieuhoa-t-vo","status":"verified","collected_at":"2026-10-28"}]},"awards":{"total":1,"shown":1,"rows":[{"value":"Developmental Therapeutics Scholar, Alex's Lemonade Stand Foundation Center of Excellence Grant (2013-present)","source_url":"https://braintumorcenter.ucsf.edu/people/kieuhoa-t-vo","status":"verified","collected_at":"2026-10-28"}]}},"similar":[{"name":"Adil Daud","slug":"adil-daud","institution":"University of California, San Francisco","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/adil-daud","json_url":"https://www.findmykol.com/kol/adil-daud/profile.json"},{"name":"Emmanuelle Waubant","slug":"emmanuelle-waubant","institution":"University of California, San Francisco","specialty":"Neurology","url":"https://www.findmykol.com/kol/emmanuelle-waubant","json_url":"https://www.findmykol.com/kol/emmanuelle-waubant/profile.json"},{"name":"Peter Ganz","slug":"peter-ganz","institution":"University of California, San Francisco","specialty":"Cardiovascular Disease","url":"https://www.findmykol.com/kol/peter-ganz","json_url":"https://www.findmykol.com/kol/peter-ganz/profile.json"},{"name":"Joel Palefsky","slug":"joel-palefsky","institution":"University of California, San Francisco","specialty":"Infectious Disease","url":"https://www.findmykol.com/kol/joel-palefsky","json_url":"https://www.findmykol.com/kol/joel-palefsky/profile.json"},{"name":"George Demetri","slug":"george-demetri","institution":"Dana-Farber Cancer Institute; Professor of Medicine","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/george-demetri","json_url":"https://www.findmykol.com/kol/george-demetri/profile.json"},{"name":"Alberto Pappo","slug":"alberto-pappo","institution":"St. Jude Children's Research Hospital","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/alberto-pappo","json_url":"https://www.findmykol.com/kol/alberto-pappo/profile.json"},{"name":"Richard Gorlick","slug":"richard-gorlick","institution":"The University of Texas MD Anderson Cancer Center","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/richard-gorlick","json_url":"https://www.findmykol.com/kol/richard-gorlick/profile.json"},{"name":"William Tap","slug":"william-tap","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/william-tap","json_url":"https://www.findmykol.com/kol/william-tap/profile.json"}],"coverage":{"note":"An identity-adjudicated profile: every section above was checked. Where a section states a count of zero, the public record was searched and nothing was found."},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"trials":9,"congress":10,"publications":3,"network":37}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts","collected_at":"2026-10-28"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies","collected_at":"2026-10-28"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year","collected_at":"2026-10-28"},"congress":{"name":"OpenAlex","url":"https://openalex.org","provides":"DOI-verified congress abstracts across AACR, ASCO, ASH, ASTRO, ESMO","disclaimer":"Congress abstracts are published as DOI-bearing journal supplements and attributed via the same ORCID-disambiguated authorship as publications.","collected_at":"2026-10-28"},"publications":{"name":"PubMed (NLM)","url":"https://pubmed.ncbi.nlm.nih.gov","provides":"Peer-reviewed publications, linked to the PubMed record","collected_at":"2026-10-28"}},"methodology_url":"https://www.findmykol.com/about#methodology"}